Abstract
We simultaneously explore the history of European Union policy on the commercialization of recombinant bovine growth hormone and the sociology of boundary drawing. We argue that, to understand why some boundary-drawing efforts succeed and others fail, we need to be attentive to the relatively stable discursive, organizational, and institutional factors that shape boundary construction. We suggest that attention to two discourses (scientism and social welfarism), the structure of policy making in the European Union, and the institutionalization of particular discourses in World Trade Organization regulations shed light on the E.U.-rbGH case.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
